text: We evaluated the clinical effectiveness of << esmolol >>, an ultra-short-acting [[ beta 1-adrenergic receptor ]] blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).